Application of corticotropin-releasing hormone receptor antagonist in preparation of inhalation anesthesia antagonist

By using NBI27914, an adrenocorticotropic hormone-releasing hormone receptor antagonist targeting the dorsal raphe nucleus, the problem of the lack of inhaled anesthetic antagonists in the prior art has been solved, enabling rapid awakening and flexible anesthesia operations, and is applicable to various inhaled anesthetic administration methods.

CN122140938APending Publication Date: 2026-06-05AFFILIATED YONGCHUAN HOSPITAL OF CHONGQING MEDICAL UNIV
1 Cites 0 Cited by

Patent Information

Application Number
CN202610451484.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-04-08
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

The existing technology lacks antagonists for inhaled anesthetics. Flumazenil cannot block the binding sites of inhaled anesthetics, resulting in long anesthesia recovery time and inflexible operating window.

Method used

By using adrenocorticotropic hormone-releasing hormone receptor antagonists, especially NBI27914, the excitatory effect of urocortin is blocked by targeting the dorsal raphe nucleus region, thereby reducing the anesthetic effect of inhaled anesthetics, shortening the recovery time, and delaying the onset of action.

Benefits of technology

It significantly shortens the anesthesia recovery time, delays the onset of anesthesia, provides a more flexible operating window, has wide applicability, is suitable for a variety of inhaled anesthetics, and has diverse routes of administration.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of inhalation anesthesia antagonism, in particular to application of an adrenocorticotropin releasing hormone receptor antagonist in preparation of an inhalation anesthesia antagonist. According to the application disclosed by the invention, the fact that the corticotropin releasing hormone receptor of the middle seam dorsal nucleus is a key target for the action of an inhalation anesthetic is found for the first time, an inhalation anesthesia effect is mediated by an ocular nerve paranuclear-middle seam dorsal nucleus neural circuit, and the corticotropin releasing hormone receptor antagonist can block an excitation effect of Urocortin on middle seam dorsal nucleus neurons; therefore, the inhalation anesthesia effect is weakened. The corticotropin-releasing hormone receptor antagonist is used for preparing the inhalation anesthesia antagonist for the first time, the technical blank in the field is filled, postoperative rapid rehabilitation of general anesthesia patients is facilitated, and wide application prospects are achieved.
Need to check novelty before this filing date? Find Prior Art